New Vision-Saving injection tested against standard for blinding eye disease
NCT ID NCT07389577
Summary
This study tested if a new eye injection called JL14002 works as well as the standard treatment (ranibizumab/Lucentis) for wet age-related macular degeneration, a leading cause of vision loss in older adults. 443 patients received either the new injection or the standard one every 4 weeks for 12 weeks, then as needed. The main goal was to see if the new treatment was as good at improving and preserving vision over one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.